Cargando…
Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
Treatment with 5α‐reductase inhibitors has been associated with sexual adverse events such as impotence (erectile dysfunction) and decreased libido. The primary objective of this study was to evaluate adverse events related to sexual function, based on their frequency, duration, persistence and asso...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055634/ https://www.ncbi.nlm.nih.gov/pubmed/29667763 http://dx.doi.org/10.1111/1346-8138.14329 |
_version_ | 1783341212609019904 |
---|---|
author | Tsai, Tsen‐Fang Choi, Gwang Seong Kim, Beom Joon Kim, Moon‐Bum Ng, Chi Fai Kochhar, Puja Jasper, Stacy Brotherton, Betsy Orban, Barbara Lulic, Zrinka |
author_facet | Tsai, Tsen‐Fang Choi, Gwang Seong Kim, Beom Joon Kim, Moon‐Bum Ng, Chi Fai Kochhar, Puja Jasper, Stacy Brotherton, Betsy Orban, Barbara Lulic, Zrinka |
author_sort | Tsai, Tsen‐Fang |
collection | PubMed |
description | Treatment with 5α‐reductase inhibitors has been associated with sexual adverse events such as impotence (erectile dysfunction) and decreased libido. The primary objective of this study was to evaluate adverse events related to sexual function, based on their frequency, duration, persistence and associated treatment discontinuations, in men treated with dutasteride for androgenetic alopecia. Participants were randomized to receive double‐blind dutasteride 0.5 mg or placebo once daily for 24 weeks, followed by open‐label dutasteride 0.5 mg for an additional 24 weeks. Sexual adverse events were followed up until resolution or for up to 24 weeks after the last dose. Overall, 117 men, 23–50 years of age, were randomized. The incidence of sexual adverse events was approximately twofold higher in the dutasteride group (16%) than the placebo group (8%) during the double‐blind period; the overall incidence of sexual adverse events was lower (5%) during the open‐label period. All adverse events were mild to moderate in severity and considered treatment‐related. The adverse events resolved while on study treatment or after the end of treatment and did not lead to treatment discontinuation. A limitation of this study was the small sample size. The sexual adverse events of impotence, decreased libido and ejaculation disorders reported in this study were expected and reversible. |
format | Online Article Text |
id | pubmed-6055634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60556342018-07-23 Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia Tsai, Tsen‐Fang Choi, Gwang Seong Kim, Beom Joon Kim, Moon‐Bum Ng, Chi Fai Kochhar, Puja Jasper, Stacy Brotherton, Betsy Orban, Barbara Lulic, Zrinka J Dermatol Original Articles Treatment with 5α‐reductase inhibitors has been associated with sexual adverse events such as impotence (erectile dysfunction) and decreased libido. The primary objective of this study was to evaluate adverse events related to sexual function, based on their frequency, duration, persistence and associated treatment discontinuations, in men treated with dutasteride for androgenetic alopecia. Participants were randomized to receive double‐blind dutasteride 0.5 mg or placebo once daily for 24 weeks, followed by open‐label dutasteride 0.5 mg for an additional 24 weeks. Sexual adverse events were followed up until resolution or for up to 24 weeks after the last dose. Overall, 117 men, 23–50 years of age, were randomized. The incidence of sexual adverse events was approximately twofold higher in the dutasteride group (16%) than the placebo group (8%) during the double‐blind period; the overall incidence of sexual adverse events was lower (5%) during the open‐label period. All adverse events were mild to moderate in severity and considered treatment‐related. The adverse events resolved while on study treatment or after the end of treatment and did not lead to treatment discontinuation. A limitation of this study was the small sample size. The sexual adverse events of impotence, decreased libido and ejaculation disorders reported in this study were expected and reversible. John Wiley and Sons Inc. 2018-04-18 2018-07 /pmc/articles/PMC6055634/ /pubmed/29667763 http://dx.doi.org/10.1111/1346-8138.14329 Text en © 2018 GlaxoSmithKline. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Tsai, Tsen‐Fang Choi, Gwang Seong Kim, Beom Joon Kim, Moon‐Bum Ng, Chi Fai Kochhar, Puja Jasper, Stacy Brotherton, Betsy Orban, Barbara Lulic, Zrinka Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia |
title | Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia |
title_full | Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia |
title_fullStr | Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia |
title_full_unstemmed | Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia |
title_short | Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia |
title_sort | prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055634/ https://www.ncbi.nlm.nih.gov/pubmed/29667763 http://dx.doi.org/10.1111/1346-8138.14329 |
work_keys_str_mv | AT tsaitsenfang prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia AT choigwangseong prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia AT kimbeomjoon prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia AT kimmoonbum prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia AT ngchifai prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia AT kochharpuja prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia AT jasperstacy prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia AT brothertonbetsy prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia AT orbanbarbara prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia AT luliczrinka prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia |